MedPath

A study comparing effectiveness of oral methadone and sublingual buprenorphine in controlling symptoms of acute withdrawal in individuals addicted to opioid drugs

Not Applicable
Not yet recruiting
Conditions
Health Condition 1: null- Patients of opioid dependence syndrome according to ICD- 10 criteria and coming to NDDTC for treatment
Registration Number
CTRI/2017/03/007977
Lead Sponsor
DDTC AIIMS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Inclusion criteria for Cases:

Male patients between 18 and 60 years of age

Diagnosis of opioid dependence syndrome according to ICD- 10 criteria

Dependent on Heroin (any route) or Injection Buprenorphine or Injection Pentazocine

Should have taken last dose of any opioid within 48 hrs of admission

Subject willing to give written informed consent

Exclusion Criteria

Exclusion criteria for Cases:

Dependence on any other substance except Nicotine

Exposure to either Buprenorphine or Methadone for treatment in preceding 3 months (either detoxification or maintenance)

Admission to any facility within last 3 month

Patients requiring other psychotropic medicines (like Benzodiazepines, TCAs, etc.) which can suppress symptoms of opioid withdrawal except hypnotic purposes

Patients on other medications which can significantly affect serum levels of Buprenorphine or Methadone either prior to admission or during admission

Any known medical contraindication to either medications

Co-morbid psychiatric illness

Patients previously randomized for this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath